Humana Inc. (BIT:1HUM)
Italy · Delayed Price · Currency is EUR | Market Cap | 31.18B +13.6% |
| Revenue (ttm) | 118.99B +14.1% |
| Net Income | 980.05M -33.9% |
| EPS | 8.12 -33.9% |
| Shares Out | n/a |
| PE Ratio | 31.81 |
| Forward PE | 27.84 |
| Dividend | 2.28 (0.86%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | n/a |
| Open | 266.00 |
| Previous Close | 266.00 |
| Day's Range | 266.00 - 266.00 |
| 52-Week Range | 133.25 - 314.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 29, 2026 |
About Humana
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial numbers in USD Financial StatementsNews
Humana completes $83M Florida infrastructure investment
Humana (HUM) announced the start of full operations of its newest CenterWell Pharmacy mail order distribution center, in Orlando, Florida. The $83M facility bolsters capacity for prescription medicati...
Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
ORLANDO, Fla.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, today announced the start of full operations of its newest CenterWell Pharmacy® ma...
Humana price target raised to $344 from $180 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $344 from $180 and keeps an Equal Weight rating on the shares. The firm believes the managed care stock moves…
Humana price target raised to $320 from $262 at UBS
UBS raised the firm’s price target on Humana (HUM) to $320 from $262 and keeps a Neutral rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected Q1…
Humana upgraded to Buy from Hold at Deutsche Bank
As previously reported, Deutsche Bank upgraded Humana (HUM) to Buy from Hold with a price target of $441, up from $235. The firm upgraded three managed care names citing a…
Humana price target raised to $335 from $290 at Mizuho
Mizuho raised the firm’s price target on Humana (HUM) to $335 from $290 and keeps an Outperform rating on the shares. The firm views the Q1 reports in the manage…
Humana upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Humana (HUM) to Buy from Hold with a $441 price target
Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...
Humana price target raised to $217 from $146 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Humana (HUM) to $217 from $146 and keeps an Underweight rating on the shares. Shares are up about 32%…
CVRx announces Humana Medicare Advantage coverage policy for Barostim therapy
CVRx (CVRX) announced that Humana (HUM) has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1. Humana provides coverage to approximately 5.2M Medicare Advantage members...
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana invests more than $1 million to advance health outcomes across Louisiana through grants that support statewide priorities.
Humana price target raised to $254 from $182 at Piper Sandler
Piper Sandler raised the firm’s price target on Humana (HUM) to $254 from $182 and keeps a Neutral rating on the shares following Q1 medical loss ratio beat where Medicare…
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Florida Seniors Face High Rates of Poor Mental Health -- A Looming Crisis as State Braces for Aging Population Boom
LOUISVILLE, Ky.--(BUSINESS WIRE)--Florida ranks among the top three states in the nation for the largest senior population, with projections showing that one-third of its residents will be over 60 by ...
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But a...
Humana price target raised to $211 from $173 at TD Cowen
TD Cowen raised the firm’s price target on Humana (HUM) to $211 from $173 and keeps a Hold rating on the shares. The firm said adj EPS $10.31 beat conensus…
Humana price target raised to $214 from $180 at JPMorgan
JPMorgan raised the firm’s price target on Humana (HUM) to $214 from $180 and keeps a Neutral rating on the shares.
Humana Earnings Call Transcript: Q1 2026
First quarter results met expectations, with strong MA and Medicaid membership growth and prudent reserving. Progress continues toward a 3%+ margin by 2028, aided by operational efficiencies, cost management, and strategic acquisitions.
Humana Earnings release: Q1 2026
Humana released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Humana Quarterly report: Q1 2026
Humana has published its Q1 2026 quarterly earnings report on April 29, 2026.
Humana Profits Eclipse $1 Billion As Medicare Costs Ease Slightly
Humana reported first quarter net income of nearly $1.2 billion as costs of care for older adults in its Medicare Advantage plans eased a bit but remained high.
Humana Profit Falls as Lower Medicare Ratings Hurt Bonuses
Humana reported lower first-quarter profit as the company faces earnings headwinds from lower Medicare Advantage Star Ratings for 2026.
Humana beats quarterly profit estimates on lower medical costs
Humana on Wednesday beat Wall Street estimates for first-quarter profit as the health insurer spent less on medical services than expected.